BGIM
ZVRA icon

Brandywine Global Investment Management’s Zevra Therapeutics ZVRA Stock Holding History

Brandywine Global Investment Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-177,900
Closed -$1.23M – 729
2024
Q3 		$1.23M Sell
177,900
-75,800
-30% -$514K 0.01% 584
2024
Q2 		$1.24M Buy
+253,700
New +$1.2M 0.01% 610

Other funds holding ZVRA

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brandywine Global Investment Management's ZVRA Position: Q4 2024 in Review

Brandywine Global Investment Management sold out of Zevra Therapeutics (ZVRA) in Q4 2024, closing a stake of 177,900 shares — an estimated $1.23M sold.

Brandywine Global Investment Management first reported a position in ZVRA in Q2 2024 and held it in 2 quarters. The position peaked at $1.24M in Q2 2024. 109 funds tracked by Wall St. Rank hold ZVRA as of Q4 2024.

  • Brandywine Global Investment Management reported no remaining Zevra Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Brandywine Global Investment Management sold 177,900 Zevra Therapeutics shares in Q4 2024, an estimated $1.23M.
  • Brandywine Global Investment Management first reported a position in Zevra Therapeutics in Q2 2024 and held it in 2 quarters.
  • Brandywine Global Investment Management's Zevra Therapeutics position peaked at $1.24M in Q2 2024.
  • 109 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2024.

Based on Brandywine Global Investment Management's 13F filing for Q4 2024, filed 12 Feb 2025.